User menu

An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole.

Bibliographic reference Jacobs, F ; Selleslag, D ; Aoun, M ; Sonet, Anne ; Gadisseur, A. An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole.. In: European Journal of Clinical Microbiology & Infectious Diseases : an international journal on pathogenesis, diagnosis, epidemiology, therapy, and prevention of infectious diseases, Vol. 31, no.6, p. 1173-9 (2012)
Permanent URL
  1. Maschmeyer Georg, Haas Antje, Cornely Oliver A, Invasive Aspergillosis : Epidemiology, Diagnosis and Management in Immunocompromised Patients, 10.2165/00003495-200767110-00004
  2. Enoch D. A., Invasive fungal infections: a review of epidemiology and management options, 10.1099/jmm.0.46548-0
  3. Marr Kieren A., Carter Rachel A., Crippa Fulvio, Wald Anna, Corey Lawrence, Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients, 10.1086/339202
  4. Ohmagari Norio, Raad Isaam I., Hachem Ray, Kontoyiannis Dimitrios P., Invasive aspergillosis in patients with solid tumors, 10.1002/cncr.20647
  5. Lin S.-J., Schranz J., Teutsch S. M., Aspergillosis Case-Fatality Rate: Systematic Review of the Literature, 10.1086/318483
  6. Kibbler C.C, Seaton S, Barnes R.A, Gransden W.R, Holliman R.E, Johnson E.M, Perry J.D, Sullivan D.J, Wilson J.A, Management and outcome of bloodstream infections due to Candida species in England and Wales, 10.1016/s0195-6701(03)00085-9
  7. European Medicines Agency (EMA) Vfend: EPAR – product information. Available at URL: . Accessed 26 September 2011
  8. Pfizer Inc. (2010) Vfend (voriconazole) US prescribing information. Last revised December 2010. . Accessed 26 September 2011
  9. Alastruey-Izquierdo A., Castelli M.V., Cuesta I., Zaragoza O., Monzón A., Mellado E., Rodríguez-Tudela J.L., In vitro activity of antifungals against Zygomycetes, 10.1111/j.1469-0691.2009.02984.x
  10. Walsh Thomas J., Pappas Peter, Winston Drew J., Lazarus Hillard M., Petersen Finn, Raffalli John, Yanovich Saul, Stiff Patrick, Greenberg Richard, Donowitz Gerald, Schuster Mindy, Reboli Annette, Wingard John, Arndt Carola, Reinhardt John, Hadley Susan, Finberg Robert, Laverdière Michél, Perfect John, Garber Gary, Fioritoni Giuseppe, Anaissie Eli, Lee Jeanette, Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever, 10.1056/nejm200201243460403
  11. Denning D. W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., Haas A., Ruhnke M., Lode H., Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis, 10.1086/324620
  12. Perfect John R., Marr Kieren A., Walsh Thomas J., Greenberg Richard N., DuPont Bertrand, de la Torre‐Cisneros Julian, Just‐Nubling Gudrun, Schlamm Haran T, Lutsar Irja, Espinel‐Ingroff Ana, Johnson Elizabeth, Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections, 10.1086/374557
  13. Herbrecht Raoul, Denning David W., Patterson Thomas F., Bennett John E., Greene Reginald E., Oestmann Jörg-W., Kern Winfried V., Marr Kieren A., Ribaud Patricia, Lortholary Olivier, Sylvester Richard, Rubin Robert H., Wingard John R., Stark Paul, Durand Christine, Caillot Denis, Thiel Eckhard, Chandrasekar Pranatharthi H., Hodges Michael R., Schlamm Haran T., Troke Peter F., de Pauw Ben, Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis, 10.1056/nejmoa020191
  14. Böhme Angelika, Ruhnke Markus, Buchheidt Dieter, Cornely Oliver A., Einsele Herrmann, Enzensberger Ruxandra, Hebart Holger, Heinz Werner, Junghanss Christian, Karthaus Meinolf, Krüger William, Krug Utz, Kubin Thomas, Penack Olaf, Reichert Dietmar, Reuter Stefan, Silling Gerda, Südhoff Thomas, Ullmann Andrew J., Maschmeyer Georg, Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), 10.1007/s00277-008-0622-5
  15. Thursky K. A., Playford E. G., Seymour J. F., Sorrell T. C., Ellis D. H., Guy S. D., Gilroy N., Chu J., Shaw D. R., Recommendations for the treatment of established fungal infections, 10.1111/j.1445-5994.2008.01725.x
  16. Walsh Thomas J., Anaissie Elias J., Denning David W., Herbrecht Raoul, Kontoyiannis Dimitrios P., Marr Kieren A., Morrison Vicki A., Segal Brahm H, Steinbach William J., Stevens David A., Burik Jo‐Anne van, Wingard John R., Patterson Thomas F., Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America, 10.1086/525258
  17. Maertens J, Marchetti O, Herbrecht R et al (2010) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 Update. Bone Marrow Transplant 46:709–718
  18. Black Nick, What Observational Studies Can Offer Decision Makers, 10.1159/000053135
  19. Van Campenhout Hilde, Marbaix Sophie, Derde Marie-Paule, Annemans Lieven, Voriconazole Treatment of Invasive Aspergillosis : Real-World versus Health-Economic Model Results, 10.2165/00044011-200828080-00006
  20. Ascioglu S., Rex J. H., de Pauw B., Bennett J. E., Bille J., Crokaert F., Denning D. W., Donnelly J. P., Edwards J. E., Erjavec Z., Fiere D., Lortholary O., Maertens J., Meis J. F., Patterson T. F., Ritter J., Selleslag D., Shah P. M., Stevens D. A., Walsh T. J., , Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus, 10.1086/323335
  21. Leather H (2005) Economic effects of aspergillosis management in high-risk patients. Manag Care Interface 18:46–52
  22. Patterson T. F., Boucher H. W., Herbrecht R., Denning D. W., Lortholary O., Ribaud P., Rubin R. H., Wingard J. R., DePauw B., Schlamm H. T., Troke P., Bennett J. E., , Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome, 10.1086/497126
  23. Slobbe Lennert, Polinder Suzanne, Doorduijn Jeanette K., Lugtenburg Pieternella J., el Barzouhi Abdelilah, Steyerberg Ewout W., Rijnders Bart J. A., Outcome and Medical Costs of Patients with Invasive Aspergillosis and Acute Myelogenous Leukemia–Myelodysplastic Syndrome Treated with Intensive Chemotherapy: An Observational Study, 10.1086/591531
  24. Álvarez-lerma F., Nicolás-Arfelis J.M., Rodríguez-Borregán J.C., Díaz-Regañón J., Sa-Borges M., García-López F., Allepuz-Palau A., Clinical Use and Tolerability of Voriconazole in the Treatment of Fungal Infections in Critically Ill Patients, 10.1179/joc.2005.17.4.417
  25. Benson Kjell, Hartz Arthur J., A Comparison of Observational Studies and Randomized, Controlled Trials, 10.1056/nejm200006223422506
  26. Herbrecht Raoul, Natarajan-Amé Shanti, Letscher-Bru Valérie, Canuet Matthieu, Invasive Pulmonary Aspergillosis, 10.1055/s-2004-824903